Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac ECM and Index Rebal

MS-Japan June 2026 Rebalance: Post-Implementation Review

MS-Japan May 2026 Rebalance: Post-Announcement Trading Pattern

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Index Rebalance

<ul>
<li>MSCI announced the quarterly review results after market close. As the cycle enters implementation, this note updates the stock setup.</li>
<li>ADDs entered implementation after a large pre-announcement move and still carry first-week give-back risk.</li>
<li>DELETEs were mild before implementation, but low-velocity DELETEs retain the weakest historical post-implementation profile.</li>
</ul>


MSCI announced the quarterly review results after market close. As the cycle enters implementation, this note updates the stock setup.
ADDs entered implementation after a large pre-announcement move and still carry first-week give-back risk.
DELETEs were mild before implementation, but low-velocity DELETEs retain the weakest historical post-implementation profile.


MS-Japan June 2026 Rebalance: Pre-Implementation Update

Furukawa Electric

MS-Japan June 2026 Rebalance: Pre-Implementation Update